Navigation Links
Haemacure Reports on Financing Progress and Second Quarter Results
Date:6/2/2008

HAE:TSX

MONTREAL, June 2 /PRNewswire-FirstCall/ - Haemacure Corporation (TSX : HAE), a Montreal-based specialty bio-therapeutics company developing high-value human plasma-derived protein products for commercialization, provides financing update and reports on second quarter results.

Financing

As a result of the commitments Haemacure has received to-date from key shareholders to exercise their Series B warrants, the Corporation is well positioned to meet its objective of commencing the fibrin sealant pivotal Phase II/Phase III clinical trials. The Corporation remains on schedule and on budget with the construction of its manufacturing facility.

"We are very appreciative and encouraged by the strong support we have received from our major shareholders, Firebird Management and Pinetree Capital, as demonstrated through the exercise of their Series B warrants." said Joseph Galli, Chairman and CEO of Haemacure. "This support, coupled with the recent addition of Reinaldo Diaz to our Board of Directors and the hiring of senior managers at our facility, are elements of our value creation strategy that will make Haemacure a significant player on the global scale." concluded Mr. Galli.

Second Quarter Results

Revenues amounted to $28,368, as compared to $24,757 for the same quarter last year. Revenues are exclusively derived from the sale of legacy fibrin sealant application devices. Operating expenses amounted to $2.5 million, as compared to $1.3 million for the same quarter last year. The increase is mainly related to the hiring of personnel, consulting expenses, supplies for the laboratory and the manufacturing facility and unusual charges. The consolidated net loss for the quarter amounted to $2.5 million, or $0.02 per share, as compared to $1.3 million, or $0.01 per share, for the same quarter last year.

Financial Position

Cash, cash equivalents and temporary investments amounted to $3.6 million as of April 30, 2008, as compared to $7.6 million as at October 31, 2007.

About Haemacure

Haemacure Corporation is a specialty biotherapeutics company developing high-value human plasma-derived protein products for commercialization. Haemacure's research and development effort is driven by its proprietary plasma protein extraction technology to develop next-generation products, including surgical hemostats. Haemacure's lead product candidate, Hemaseel(R)HMN, is a fibrin sealant to enter pivotal Phase II/Phase III clinical trials during the first quarter of 2009. Haemacure's second product candidate is thrombin, a component of its fibrin sealant, now in preclinical stage. Follow-on development will focus on surgical hemostats, wound healing, adhesion prevention, regenerative medecine, drug delivery and combination with biomaterials. Haemacure has discovered eleven additional specialty proteins and enzymes in one if its two plasma fractions and seeks to advance these proteins and enzymes through partnerships with pharmaceutical and biotechnology companies. Haemacure operates offices in Sarasota, Florida through a wholly-owned subsidiary. The Corporation is traded under stock symbol HAE on the TSX.

Forward-looking Statements

Certain of the statements contained in this news release are forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the biotech industry, changes in the regulatory environment in the jurisdictions in which Haemacure does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. Haemacure disclaims any intention or obligation to update these statements.

Financial Highlights

(unaudited)

Quarters ended

April 30, 2008 April 30, 2007

-------------- --------------

Sales $28,368 $24,757

Gross profit $15,825 $11,725

Gross margin 56% 47%

General and administrative expenses $1,327,551 $1,177,120

Research and development expenses $668,452 $205,224

Other expenses $468,824 -

Total expenses $2,520,807 $1,313,800

Net loss $(2,504,982) $(1,302,075)

Loss per share $(0.02) $(0.01)

Weighted average number of shares

outstanding 163,800,917 163,800,917

As at As at

April 30, 2008 October 31, 2007

-------------- ----------------

Cash and cash equivalents $919,364 $3,591,883

Temporary investment $2,657,716 $4,011,200

Total assets $9,582,260 $10,939,289

Shareholders' equity $5,984,485 $9,226,329


'/>"/>
SOURCE HAEMACURE CORPORATION
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Haemacure to Present at Busines$ Meets Finance on May 20, 2008 at the Montreal Sheraton Centre
2. Haemacure announces webcast of presentation at Rodman & Renshaw 5th Annual Global Healthcare Conference
3. Haemacure financing receives shareholder consent - Series B Warrants are amended
4. Haemacure to Present at the BioFinance 2008 Conference to be held at the Toronto Marriott Eaton Centre, May 6 - 8, 2008
5. Haemacure Discloses Positive Results of a preclinical study of its fibrin sealant in adhesion prevention and opens a new opportunity in a market with a significant unmet medical need
6. Haemacure Reports on its annual general and special meeting of shareholders
7. Media Invitation - Annual General and Special Meeting of Shareholders of Haemacure
8. Haemacure Announces Details of its Annual General and Special Meeting of Shareholders
9. Haemacure announces webcast of presentation at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conferencec
10. Haemacure Adopts Strategy for "First-Patient-In" Fibrin Sealant Pivotal Clinical Trials
11. Haemacure Reports Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... Battle Creek, MI (PRWEB) , ... January 17, 2017 , ... ... substance abuse located in Southwest Michigan, joined other volunteers and organizations in support of ... sees hundreds of children and families dressed up in colorful costumes of all designs ...
(Date:1/16/2017)... ... January 16, 2017 , ... ... their groundbreaking GunSport•PRO® and EB15•LE® electronic earplugs at the NSSF SHOT Show on ... Booth #2809. The SHOT Show is the shooting, hunting and outdoor trade show ...
(Date:1/16/2017)... , ... January 16, 2017 , ... ... , Antoine Dental Center, is currently offering complimentary consultations and financing for orthodontics ... teeth examined for bite irregularities and learn about their orthodontic options. Walk-in, late-evening, ...
(Date:1/16/2017)... ... 2017 , ... Specialty Technical Publishers (STP) and Specialty Technical ... (IAPC) EHS audit protocol for Singapore . Leading companies around the world ... obligations and rapidly collect, share, archive, and export audit findings in a cost ...
(Date:1/16/2017)... ... January 16, 2017 , ... ... science teacher, http://www.ageofautism.com/legal , Sharon Kleyne, America’s leading water educator, researcher ... her nationally syndicated radio program, The Sharon Kleyne Hour Power of Water, Global ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... BAUDETTE, Minn. , Jan. 17, 2017 /PRNewswire/ ... ) today announced the appointment of Karen Quinn ... January 17, 2017.  Karen ... years of leadership experience in Global Regulatory Affairs, ... biologically-derived active pharmaceutical ingredients.  Dr. Quinn worked most ...
(Date:1/17/2017)... pioneer in no-touch UV disinfection has now been validated by ... for "total room ultraviolet disinfection," was the device of choice ... study which was recently published in The Lancet ... transmission of four major superbugs by a cumulative 30 percent. ... we have been committed to innovation and the science behind ...
(Date:1/16/2017)... Research and Markets has announced the addition ... to their offering. ... Global multiple myeloma drugs market to grow at a CAGR ... covers the present scenario and the growth prospects of the global ... the report considers the revenue generated from the sales of branded ...
Breaking Medicine Technology: